Form 8-K - Current report:
SEC Accession No. 0001628280-23-017420
Filing Date
2023-05-11
Accepted
2023-05-11 08:08:09
Documents
12
Period of Report
2023-05-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K prme-20230510.htm   iXBRL 8-K 34714
  Complete submission text file 0001628280-23-017420.txt   176371

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20230510.xsd EX-101.SCH 1917
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20230510_lab.xml EX-101.LAB 24832
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20230510_pre.xml EX-101.PRE 13053
6 EXTRACTED XBRL INSTANCE DOCUMENT prme-20230510_htm.xml XML 12731
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 23908946
SIC: 2836 Biological Products, (No Diagnostic Substances)